Core Viewpoint - Yifan Pharmaceutical (002019) announced that the company and its controlling subsidiaries have not provided guarantees for units outside the scope of the consolidated financial statements, nor do they have overdue guarantees, litigation-related guarantee amounts, or losses due to judgments against guarantees [1] Group 1 - The company has not provided any guarantees for units outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - The company has not incurred any losses due to judgments related to guarantees [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2026-009 亿帆医药股份有限公司 关于在下属子公司之间调剂担保额度及为全资子公司提供担保 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保额度调剂情况 亿帆医药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开的第 八届董事会第十六次会议及 2025 年 5 月 20 日召开的 2024 年年度股东会，均审 议通过了《关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内 担保额度的议案》，同意公司及控股公司向各家金融机构申请总额度不超过人民 币 650,000 万元（或等值外币）的综合授信融资，申请纳入公司合并报表范围内 的公司相互提供担保，担保额度合计不超过人民币 600,000 万元（或等值外币）， 授权期限为自 2024 年年度股东会审议通过之日起 12 个月内有效，额度范围内可 循环使用。 上述内容具体详见公司于 2025 年 4 月 28 日及 2025 年 5 月 21 日在巨潮资讯 网上披露的《第八届董事会第十六次会议决议公告》（公告编号： ...

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2026年1月30日收到国家药品监督管理局核准签发的维生素K1注射液 《药品注册证书》。现将相关情况公告如下： 证券代码：002019 证券简称：亿帆医药 公告编号：2026-008 亿帆医药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、药品注册证书主要信息 1、药品名称：维生素K1注射液 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品3类 5、规格：1ml:10mg 6、药品受理号：CYHS2401632 7、证书编号：2026S00290 8、药品批准文号：国药准字H20263243 9、药品批准文号有效期：至2031年01月26日 三、对公司的影响及风险提示 本次《药品注册证书》的取得，扩大了公司维生素K1注射液的适应症范围和 适用人群，将提升该产品在该药品领域的综合竞争力。上述产品的具体经营情况 受国家政策、市场竞争环境等因素影响，具有不确定性。敬请广大投资者谨慎决 策，注意投资风险。 亿帆医药股份 ...

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical (002019) acknowledges that the sales ramp-up of its new drug requires a certain cultivation period, indicating that the product is still in the early stages of market introduction [1] Group 2 - Yifan Pharmaceutical's new drug, Yilishu, is currently in the initial phase of market penetration, suggesting that it may take time before significant sales are realized [1]

Core Viewpoint - Yifan Pharmaceutical emphasizes the importance of shareholder concerns and market value management, committing to standardized operations and multiple measures to stabilize its market value [2] Group 1 - The company is focused on enhancing its main business profitability [2] - The company aims to optimize its product structure [2] - The company is working on reducing production costs [2] Group 2 - The company is strengthening information disclosure and investor communication [2] - The company believes that its market value will align with its intrinsic value through effective management [2]

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical is committed to timely disclosure regarding the new regional sales of Yilishu and will communicate investor concerns about its overseas market performance to management [2] Group 2 - Yifan Pharmaceutical responded to investor inquiries on its interactive platform, indicating that it will follow regulations for any new regional market launches of Yilishu [2] - The company acknowledges the importance of investor feedback regarding the overseas market performance of Yilishu [2]

（文章来源：证券日报） 证券日报网讯 1月27日，亿帆医药在互动平台回答投资者提问时表示，截至2026年1月9日公司股东人数 为49170户。 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：公司好多年以来，都处于业务转型和泛酸钙价格跌跌 不休阶段，因此长线投资者听到看到的一直都是业绩预减消息。2025年最后一天，公司通过微信公众号 发布了创新药627以及易尼康和希罗达等销量大幅增长的好消息。请问，2025年报业绩能艰难地预增一 次吗？这次还会有大量各种计提吗？ 亿帆医药（002019.SZ）1月27日在投资者互动平台表示，具体业绩请您查阅届时公司拟于2026年4月24 日披露的2025年年度报告，请您持续关注公司公告。 ...